Menu Search
Equities

Organovo Holdings Inc

4OR1:FRA

Organovo Holdings Inc

Actions
  • Price (EUR)0.590
  • Today's Change0.085 / 16.83%
  • Shares traded2.08k
  • 1 Year change-63.85%
  • Beta--
Data delayed at least 15 minutes, as of Jul 24 2024 16:08 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Organovo Holdings, Inc. is a clinical-stage biotechnology company. The Company is focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues, as well as preclinical data. Its segments include research and development (R&D) and Mosaic Cell Sciences (Mosaic). It is also focused on building high fidelity, 3D tissues that recapitulate key aspects of human disease. It uses its proprietary technology to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. Its Mosaic division to serve as a key source of certain primary human cells it utilizes in its research and development efforts. Its 3D human tissue platform is multifaceted. Its NovoGen Bioprinters can also dispense pure hydrogel formulations, provided the physical properties of the hydrogel are compatible with the dispensing parameters.

  • Revenue in USD (TTM)109.00k
  • Net income in USD-14.67m
  • Incorporated2012
  • Employees12.00
  • Location
    Organovo Holdings IncSuite 100, 11555 Sorrento Valley RoadSAN DIEGO 92121United StatesUSA
  • Phone+1 (858) 224-1000
  • Fax+1 (302) 636-5454
  • Websitehttps://organovo.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.